3 results
Approved WMOPending
Part 1: dose optimizationTo identify a clinically active and tolerable systemic exposure range of bezuclastinib in subjects with AdvSMPart 2 Stage 1: Dose ConfirmationTo confirm the optimal dose of bezuclastinib in subjects with AdvSMPart 2 Stage 2…
Approved WMORecruiting
To test whether the proportion of patients in remission during the last 6 months of follow up is higher for a T2T strategy compared to a T2S stop strategy.
Approved WMORecruiting
To collect clinical and device performance outcomes data with the ACURATE neo2* Transfemoral Aortic Valve System as used inroutine clinical practice for the treatment of severe calcific aortic stenosis.